Merz Pharma GmbH & Co. KGaA is a privately-held pharmaceutical company based in Frankfurt, Germany with affiliates across Europe, as well as the US, Canada, Mexico, Brazil and Asia Pacific and regional headquarters in Singapore and North Carolina, USA.The company is active in research, development and distribution of products in the areas of aesthetic medicine and neurologically induced movement disorders. In German-speaking countries, the Merz consumer products business, Merz Consumer Care, is a provider of health, wellness and beauty products with its tetesept and Merz Spezial brands.Today, Merz’s global businesses are focused on the areas of medical aesthetics and neurotoxin therapy, supported by regional brands in both the prescription medicine and consumer health and beauty sectors. Key brands in the Merz Aesthetics portfolio include Belotero, Radiesse, Cellfina, Ultherapy, Botulinum Toxin and Neocutis (US only).
The use of botulinum toxin therapy to correct spasticity and sialorrhea in a single injection session is an adequate treatment strategy for children with cerebral palsy (CP), as these two conditions are often observed simultaneously in patients and negatively affect the course of the disease and quality of life. Objective: to evaluate the efficacy and safety of simultaneous correction of spasticity and sialorrhea with incobotulinumtoxin A in patients with CP. Material and methods . A retrospective analysis was conducted of the medical records of pediatric patients with spastic forms of CP with varying levels of motor ability (from level I to level V according to the Gross Motor Function Classification System, GMFCS) who had spasticity and sialorrhea of varying severity. The analysis included only those patients who underwent simultaneous correction of spasticity and sialorrhea with incobotulinumtoxin A during a single injection session. The total average dose for the correction of spasticity of the upper limbs (UL) and lower limbs (LL), the average dose for the correction of sialorrhea, the total average and maximum dose of the drug per injection session, the dynamics on the modified Ashworth scale (MAS) and the Drooling Impact Scale (DIS), as well as the overall improvement in sialorrhea on the Global Impression of Change Scale (GICS) during treatment were assessed. The severity of the therapeutic effect of the drug after repeated injections was studied, and an analysis of adverse events (AEs) was performed throughout all injection cycles. The analysis included 162 patients with a mean age of 7.23±3.73 years. Spastic tetraparesis was present in 46.9% of patients, spastic diplegia in 46.3%, and hemiplegic form in 6.8%. 3.1% of patients had GMFCS I, 19.1% had GMFCS II, 18.5% had GMFCS III, 44.4% had GMFCS IV, and 14.8% had GMFCS V. Initially, the severity of spasticity in the upper limbs was 2.33±0.71 points on the MAS, and spasticity in the lower limbs was 2.67±0.74 points on the MAS. The severity of sialorrhea on the DIS scale was 72.96±13.21 points. Results . All patients underwent one injection cycle (IC), of which 40.1% underwent two ICs, 19.1% underwent three ICs, and 12.3% underwent four ICs. The average dose for correction of spasticity of the upper limbs was 77.10±57.53 U, for NC – 157.10±68.59 U, for sialorrhea – 41.91±19.15 U, the average total dose of the drug per IC – 257.65±92.86 U (13.19±3.91 U/kg), maximum dose – 500 U. After the first IC, UL spasticity decreased by an average of 1.18 points on the MAS, and UL spasticity decreased by 1.23 points. The DIS sialorrhea score decreased by 27.3 points. Repeated ICs showed similar efficacy in correcting spasticity and sialorrhea. The overall improvement in sialorrhea on the GICS scale averaged 1.70±0.51 points after the first IC, and by the fourth IC it increased to 2.00±0.46 points, i.e., a tendency toward an increase in effect was noted. After the first IC, 8% of patients experienced AEs, most commonly pain at the injection site, less commonly dry mouth, increased saliva viscosity, and fever. The frequency of AEs did not increase with repeated ICs. Conclusion . Simultaneous treatment of spasticity and sialorrhea is a highly effective and safe approach in patients with CP. Repeated injections of incobotulinumtoxin A maintain the high efficacy and safety of this comprehensive therapeutic approach.
BACKGROUND: The Centers for Medicare & Medicaid Services (CMS) is the single largest payer for health care in the United States and the largest payer by spending globally. Medicare Part B, with more than 50 million beneficiaries, currently has no broad mechanisms in place for promoting cost-effective care of injectable drugs. OBJECTIVE: To conduct a real-world utilization and cost analysis comparing botulinum toxins in movement disorders. METHODS: The 2017 Medicare Provider Utilization and Payment Data: Physician and Other Supplier dataset from CMS was used for this claims level analysis. Neurologists, ophthalmologists, or physiatrists who injected predominantly for movement disorders (defined as blepharospasm, cervical dystonia, sialorrhea, and/or spasticity) were included along with their patients. Botulinum toxins with FDA indications spanning these 3 specialties were included. RESULTS: A total of 891 physicians (406 ophthalmologists, 338 neurologists, and 147 physiatrists) along with their 29,954 botulinum toxin (27,441 onabotulinumtoxinA and 2,513 incobotulinumtoxinA) patients were included in the analysis. The average total drug cost per patient per year (PPPY) was significantly lower for incobotulinumtoxinA versus onabotulinumtoxinA ($2,099 vs. $3,115; P < 0.001), for an average savings of 32.6%. Annual average out-of-pocket costs were also significantly less expensive for incobotulinumtoxinA versus onabotulinumtoxinA ($486 vs. $719; P < 0.001), for an average savings of 32.4%. Across 74,346 total injection visits, there was no significant difference in dosing between the agents, with an average dosing ratio of 0.94 incobotulinumtoxinA to 1.0 onabotulinumtoxinA. Injections PPPY were 2.42 for onabotulinumtoxinA and 2.29 for incobotulinumtoxinA. Average reported wastage was 64% higher for onabotulinumtoxinA than it was for incobotulinumtoxinA. A budget impact analysis estimated that increasing incobotulinumtoxinA use in the movement disorder space to attain an overall 20% botulinum toxin market share would save Medicare $32.9 million over a 3-year period versus current use. CONCLUSIONS: IncobotulinumtoxinA was shown to be a less costly alternative than onabotulinumtoxinA with similar dosing in realworld practice in this large national Medicare population. Policies to increase use of agents that promote cost-effective evidence-based care should be further explored and implemented for this fundamental federal payer.
Botulinum neurotoxin A (BoNT/A) products recently introduced for medical esthetic use, including Nabota/Jeuveau, Meditoxin/Neuronox, and Botulax, contain nontoxin accessory proteins (NAPs) and excipients. Our objective is to show that there is scarce, publicly-available, clinical evidence of these toxins’ purity, potential immunogenicity or their links to treatment failures. This study aimed to review the issues surrounding BoNT/A-induced immunogenicity and antibody-induced treatment failures. We examined reports on the immunogenicity of BoNT/A and its complexing proteins, and the impact of toxin-specific (eg contaminating antigenic and accessory proteins) and treatment-related factors (eg total toxin dose and injection frequency). We discuss multiple patients who presented to a single clinic for resolution of previous treatment failures caused by the use of toxins containing complexing proteins elsewhere. It is important to understand a toxin’s true composition and the justifications for the presence of any non-toxin elements or high neurotoxin quantities in some formulations, which increases the risk of neutralizing antibody (NAB) formation and treatment failures. We highlight the inadequate clinical evidence supporting the recently introduced toxins, as well as their potential antigenic protein loads and the impacts of these entities on NAB formation. Our patient cases illustrate an increasing and worrying incidence of such treatment failures. If suboptimal clinical outcomes occur, physicians must consider the possibility of immunogenicity. The most prudent approach is to prevent NAB formation and treatment nonresponsiveness from the start by using only formulations with no adjuvant proteins and only the active neurotoxins without inactive components, such as incobotulinumtoxinA.
Purpose The efficacy of microfocused ultrasound with visualization (MFU-V; Ultherapy®) has been demonstrated in clinical studies and daily practice. However, data addressing skin physiology after MFU-V treatment are lacking. This observational evaluation was aimed to assess skin physiology before and after MFU-V treatment using noninvasive biophysical measurements. Patients and methods Twenty-two female patients with moderate-to-severe skin sagging at the jawline and submental region on the Merz Aesthetics Scale obtained a single MFU-V treatment according to protocol. Skin function measurements focused on short-term effects up to 3 days and long-term effects up to 24 weeks after treatment. Skin temperature, transepidermal water loss, skin hydration, erythema, elasticity, and skin thickness and density were evaluated under standardized conditions. Pain was assessed using a validated numeric visual analog scale. Results Skin temperature remained in a physiologic range and no significant increase was noted at day 3 after MFU-V treatment. Transepidermal water loss, hydration, and erythema values were fairly stable and showed no significant differences at short- and long-term measurements vs baseline. At week 4 after a single MFU-V treatment, gross and net elasticity values were significantly decreased (P=0.003 and P=0.0001, respectively), followed by significantly increased values at week 12 (P=0.015, P=0.046) and week 24 (P=0.001, P=0.049). Edema due to MFU-V treatment resolved without sequelae. For all patients, pain diminished shortly after treatment. No adverse events occurred during the 24-week follow-up period. Conclusions MFU-V treatment is well tolerated and it does not alter the epidermal barrier function or physiology of skin. Significant increase in the elasticity of skin was observed at 12 and 24 weeks after a single treatment, which reflects improvement in dermal tissue function. These short- and long-term effects are congruous with the mode of action of MFU-V due to a proven intrinsic tissue remodeling process.
PM&RVolume 9, Issue 9S1 p. S282-S282 Category: Neurological Rehabilitation Poster 471: SIAXI: Efficacy and Safety of IncobotulinumtoxinA for the Treatment of Sialorrhea in Parkinson's Disease (PD), Stroke, and Other Neurological Conditions: Results of a Phase III, Placebo-Controlled, Randomized, Double-Blind Study Andrew Blitzer MD, Andrew Blitzer MD Columbia University, New York, NY, United StatesSearch for more papers by this authorAndrzej Friedman MD, Andrzej Friedman MD Columbia University, New York, NY, United StatesSearch for more papers by this authorOlaf Michel MD, Olaf Michel MD Columbia University, New York, NY, United StatesSearch for more papers by this authorBirgit Flatau-Baqué MD, Birgit Flatau-Baqué MD Columbia University, New York, NY, United StatesSearch for more papers by this authorJános Csikós MD, János Csikós MD Columbia University, New York, NY, United StatesSearch for more papers by this authorWolfgang Jost MD, Wolfgang Jost MD Columbia University, New York, NY, United StatesSearch for more papers by this author Andrew Blitzer MD, Andrew Blitzer MD Columbia University, New York, NY, United StatesSearch for more papers by this authorAndrzej Friedman MD, Andrzej Friedman MD Columbia University, New York, NY, United StatesSearch for more papers by this authorOlaf Michel MD, Olaf Michel MD Columbia University, New York, NY, United StatesSearch for more papers by this authorBirgit Flatau-Baqué MD, Birgit Flatau-Baqué MD Columbia University, New York, NY, United StatesSearch for more papers by this authorJános Csikós MD, János Csikós MD Columbia University, New York, NY, United StatesSearch for more papers by this authorWolfgang Jost MD, Wolfgang Jost MD Columbia University, New York, NY, United StatesSearch for more papers by this author First published: 19 September 2017 https://doi.org/10.1016/j.pmrj.2017.08.416Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume9, Issue9S12017 AAPM&R Annual Assembly AbstractsSeptember 2017Pages S282-S282 RelatedInformation